MCL Literature Feed
21 papers on mantle cell lymphoma from PubMed. Updated daily.
Consensus guidelines recommend the BOVen triplet (zanubrutinib, obinutuzumab, venetoclax) for TP53-mutated MCL and CAR-T for BTKi-refractory disease, providing expert guidance for managing high-risk patients.
An expert panel opinion advocates for personalized MCL therapy, positioning BTKi as a frontline standard for transplant-ineligible patients and a potential alternative to consolidation transplant for others.
This Delphi consensus provides a framework to overcome CAR-T referral barriers in MCL, emphasizing early patient identification and structured collaboration between centers to improve access and timeliness of therapy.
The Japanese PMDA has approved the BTK inhibitor acalabrutinib for treating mantle cell lymphoma, providing a new therapeutic option for patients in Japan.
NCCN guidelines now highlight BTK inhibitor-based regimens as effective options for high-risk, TP53-mutated classical mantle cell lymphoma, formalizing a key strategy for this difficult-to-treat population.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
The EHA-EU MCL network published comprehensive guidelines standardizing risk-stratified diagnosis and treatment for MCL, covering young/fit and elderly patients in both frontline and relapsed/refractory settings.
This review argues that new agents like BTKi are disrupting the frontline MCL standard of care, challenging ASCT's role and demanding personalized, risk-adapted treatment guidelines to resolve clinical uncertainty.
This review summarizes recent phase II/III trial data supporting the integration of covalent BTK inhibitors into frontline MCL therapy, proposing new treatment algorithms for this setting.
This conference report identifies key controversies in B-cell lymphoma management, initiating a formal process to develop expert consensus guidelines for navigating increasingly complex treatment selection and sequencing decisions.
The Japanese Society of Hematology's 2023 guidelines provide updated, evidence-based recommendations on risk stratification and treatment algorithms for managing mantle cell lymphoma in clinical practice.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This review contrasts European and American perspectives on integrating autologous transplant, CAR-T, and allogeneic transplant into MCL treatment, offering clinical guidance in a rapidly evolving therapeutic landscape.
The recent FDA approval of Lisocabtagene Maraleucel provides a new CAR-T therapy for relapsed/refractory MCL, offering high response rates but requiring careful management of severe toxicities.
The Australasian Lymphoma Alliance provides consensus guidelines for MCL diagnosis and management, integrating novel therapies and risk-stratification using biomarkers like TP53, blastoid morphology, and high Ki67.
Italian experts established consensus diagnostic and therapeutic pathways for MCL, standardizing care while highlighting ongoing debates on MRD utility, immunotherapy sequencing, and CAR-T versus bispecifics.
The non-covalent BTK inhibitor pirtobrutinib is now approved in Japan for mantle cell lymphoma, providing a crucial new therapeutic option for patients, including those resistant to covalent BTKis.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
A survey of US and European hematologists reveals significant knowledge gaps in MCL guidelines, molecular testing, and toxicity management, highlighting a need for improved continuing medical education.
This article summarizes Israeli national guidelines for administering CAR-T therapy in relapsed/refractory MCL, detailing patient management, toxicity monitoring for CRS and ICANS, and long-term follow-up principles.
This review analyzes the regulatory challenges and decision-making complexities for ibrutinib in MCL, stemming from inconsistent results across different pivotal clinical trials.
This paper proposes using the estimand framework to standardize definitions of Duration of Response (DOR) and Time to Response (TTR), using an MCL case study to improve trial endpoint clarity.
The British Society for Haematology provides updated, evidence-based guidelines on MCL diagnosis, risk stratification, and treatment algorithms, standardizing care for UK patients.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This commentary highlights the new British Society for Haematology guidelines, offering updated, comprehensive recommendations for MCL diagnosis and management, including guidance for difficult-to-treat clinical scenarios.